Phase I study of the mitomycin C analogue BMS41 81174
1998

Phase I Study of BMS-181174

Sample size: 82 publication Evidence: low

Author Information

Author(s): VM Macaulay, KJ O'Byrne, JA Green, PA Philip, L McKinley, FP LaCreta, B Winograd, TS Ganesan, AL Harris, DC Talbot

Hypothesis

Does BMS-181174 have anti-cancer activity and what are its toxicity levels?

Conclusion

BMS-181174 has anti-cancer activity but is associated with significant toxicity, leading to no further phase II studies being planned.

Supporting Evidence

  • BMS-181174 was administered to 82 patients with confirmed malignancy.
  • The maximum-tolerated dose was found to be 65 mg/m2 in previously treated patients.
  • Partial response rate was 5% overall and 9% in patients treated at higher doses.
  • Significant toxicities included myelosuppression and thrombophlebitis.

Takeaway

This study tested a new cancer drug on 82 patients to see if it works and how safe it is. It helped a few people but also caused serious side effects.

Methodology

Patients with confirmed malignancy received BMS-181174 intravenously at varying doses every 28 days, with evaluations of toxicity and response.

Limitations

The study was limited by the high toxicity of the drug, which prevented further testing.

Participant Demographics

{"total":82,"age":{"median":59,"range":"20-73"},"sex":{"male":42,"female":40},"previous_treatment":{"chemotherapy":52,"radiotherapy":28}}

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication